Jefferies Hires Former Biotech Analyst Amin from WJB Capital Group
Posted by The PIPEs Report on August 24, 2011
Biren Amin was appointed as a managing director and senior research analyst covering biotechnology c…
Source >>>
Rodman & Renshaw Hires Bankers in Biotech, Health Care, Shipping
Posted by The PIPEs Report on July 11, 2011
Rodman & Renshaw said it hired three investment bankers to boost its business advising the biotechno…
Source >>>
Rodman & Rensahw Hires Bankers in Biotech, Health Care, Shipping
Posted by The PIPEs Report on
Rodman & Renshaw said it hired three investment bankers to boost its business advising the biote…
Source >>>
Former Reverse Merger Company Champions Biotech Raises $9.4M in PIPE
Posted by admin on April 1, 2011
Champions Biotechnology, a medical technology and cancer drug developer, raised $9.4 million in a pr…
Source >>>
Sanofi says Genzyme takeover talks progressing
Posted by Reuters: Business News on February 9, 2011
PARIS (Reuters) – Sanofi-Aventis reported progress in talks to buy U.S. biotech Genzyme and predicted 5-10 percent lower earnings in 2011, underscoring the French drugmaker’s need to find new sources…
Sanofi, Genzyme takeover talks enter final stretch
Posted by Reuters: Business News on February 7, 2011
PARIS/BOSTON (Reuters) – France’s Sanofi-Aventis and U.S. biotech Genzyme kept investors in suspense about their $20 billion transatlantic pharmaceuticals merger on Monday, as sources predicted a…
Sanofi extends $18.5 billion Genzyme offer to Jan 21
Posted by Reuters: Business News on December 13, 2010
PARIS (Reuters) – Sanofi-Aventis extended its $18.5 billion cash offer for U.S. biotech Genzyme until January 21 on Monday and left open the option to prolong it further in a sign the French…
J&J sticks to $2.4 billion bid for Crucell
Posted by Reuters: Business News on October 6, 2010
AMSTERDAM (Reuters) – Crucell said it would recommend U.S. personal care group Johnson & Johnson’s unchanged cash offer of 24.75 euros per share for the Dutch biotech as one shareholder said he…
J&J aiming to buy vaccine maker Crucell for $2.3 billion
Posted by Reuters: Business News on September 17, 2010
AMSTERDAM/NEW YORK (Reuters) – Johnson & Johnson is in talks to pay 1.75 billion euros ($2.3 billion) to buy Dutch biotech Crucell as it seeks to catapult itself into the global vaccine market.
Johnson & Johnson aims to buy vaccine maker Crucell
Posted by Reuters: Business News on
AMSTERDAM (Reuters) – U.S. health care company Johnson & Johnson , looking to catapult itself into the global vaccine market, is in talks to pay 1.75 billion euros ($2.3 billion) to buy Dutch biotech Crucell .
